Recently, the State Food and Drug Administration announced that based on comprehensive monitoring and evaluation results both domestically and internationally, the use of sibutramine may increase the risk of serious cardiovascular diseases. The risks of using sibutramine for weight loss outweigh the benefits. Therefore, it has been decided to stop the production, sale, and use of sibutramine preparations and raw materials in China. The marketed drugs will be recalled and destroyed by the manufacturing companies. The products that have been banned include various weight loss drug brands such as Qumei, Aoquqing, Kexiu, Saisimei, Quting, Puxiu, Tingli, Aolina, Qujing, Xinfenmeilin, Xiqing, Shenzhihua, Hengyun, Miaole, and Nuomeiting, among others.
The National Medical Products Administration advises that whether it is for treating obesity or for individuals who want to achieve body shaping by reducing weight, they should adhere to a scientific lifestyle in the long term to maintain weight and reduce rebound. It is recommended that patients who are currently using sibutramine consult their doctors in a timely manner to discuss alternative medications.
